HSA Approves New JAK inhibitor Abrocitinib (Cibinqo) For The Treatment of Atopic DermatitisBy KayeMay 5, 20220 The disease burden and current treatment landscape Atopic dermatitis (AD), or eczema, is the most common skin disorder in Singapore…
